Lily Chen, MD
Cardiovascular Disease · Sacramento, CANPI 1861819815
Payments from drug & device makers
Across 339 payments — averaging $219.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$33K
- Abbott$14K
- Philips North America LLC$9K
- Boston Scientific$5K
- Edwards Lifesciences$2K
- W. L. Gore & Associates, Inc.$2K
- plus $10K from 26 others
What the payments were for
- Consulting fees$9,53813%
- Grants$41,44056%
- Travel & lodging$4,1306%
- Food & beverage$18,96726%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $32,955 |
| Abbott | 39 | $13,539 |
| Philips North America LLC | 4 | $9,047 |
| Boston Scientific | 67 | $4,998 |
| Edwards Lifesciences | 20 | $2,165 |
| W. L. Gore & Associates, Inc. | 16 | $1,963 |
| Biotronik Inc. | 23 | $1,899 |
| Siemens Medical Solutions USA, Inc. | 5 | $1,534 |
| Abiomed | 27 | $1,385 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $1,130 |
| Shockwave Medical, Inc | 20 | $704 |
| Chiesi USA, Inc. | 10 | $375 |
| Amgen | 15 | $347 |
| Novartis | 12 | $260 |
| Asahi Intecc USA, Inc. | 3 | $236 |
| Atricure, Inc. | 2 | $228 |
| Inari Medical, Inc. | 1 | $197 |
| Pfizer | 8 | $193 |
| Teleflex LLC | 1 | $170 |
| E.r. Squibb & Sons, L.L.C. | 8 | $156 |
| Cathworks, Inc. | 1 | $143 |
| AstraZeneca | 6 | $94 |
| Penumbra, Inc. | 2 | $93 |
| Regeneron Healthcare Solutions, Inc. | 5 | $90 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Merck | 3 | $76 |
| Inspire Medical Systems, Inc. | 1 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Johnson & Johnson | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$17,146
- (9520) IGT Devices Undivided$8,938
- GORE CARDIOFORM Septal Occluder$1,669
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,271
- WATCHMAN Access System$1,095
- OMNILINK ELITE$600
- AVVIGO Guidance System$589
- MitraClip$583
- AMPLATZER PICCOLO$536
- Solia$533
- BioMonitor$533
- Rivacor$533
- Edora$533
- Acticor$533
- LifeVest$464
- AMPLATZER$425
- Micra$420
- Impella$399
- Acticor 7 VR-T DX$389
- XIENCE SIERRA$349
How this compares
$74,267 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $215,912 |
| EntrestoSacubitril/Valsartan | 50 | $48,672 |
| XareltoRivaroxaban | 17 | $28,078 |
| Praluent PenAlirocumab | 20 | $14,229 |
| FarxigaDapagliflozin Propanediol | 13 | $10,301 |
| Atorvastatin Calcium | 244 | $3,135 |
| Metoprolol Succinate | 173 | $2,530 |
| Rosuvastatin Calcium | 95 | $1,392 |
| Amlodipine Besylate | 184 | $1,158 |
| Losartan Potassium | 88 | $1,143 |
| Valsartan | 21 | $973 |
| Bisoprolol Fumarate | 33 | $884 |
| Carvedilol | 72 | $658 |
| Bumetanide | 12 | $568 |
| ClopidogrelClopidogrel Bisulfate | 51 | $561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $193 | $215,912159 claims |
| NovartisEntresto | $260 | $48,67250 claims |
| Johnson & JohnsonXarelto | $30 | $28,07817 claims |
| AstraZenecaFarxiga | $94 | $10,30113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$5.1M
- Gagan SinghSacramento$2M
- Jeffrey SouthardSacramento$1.8M
- Thomas SmithSacramento$942K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.